Higher glucose level and systemic oxidative stress decrease the mean velocity index of the retinal artery during flickering light stimulation in type 1 diabetes

Aim To determine whether higher glucose level and systemic oxidative stress decrease mean velocity (MV) index of the central retinal artery (CRA) during flickering light stimulation in type 1 diabetes (T1D).

Methods The study was performed in the period from 2008 to 2015 at the University Eye Clinic in Ljubljana. 41 patients with T1D and 37 participants without diabetes were included. MV in the CRA was measured using Doppler ultrasound diagnostics in basal conditions and during 8 Hz flickering light irritation. The plasma levels of glucose, fructosamine, 8-hydroxy-2'-deoxyguanosine (8-OHdG), triglycerides, cholesterol, and low-density lipoprotein (LDL) were measured.

Results Patients with T1D had significantly higher levels of blood glucose ($P<0.001$), fructosamine ($P<0.001$), and 8-OHdG ($P<0.001$), but there were no significant differences in triglycerides ($P=0.108$), cholesterol ($P=0.531$), and LDL ($P=0.645$) between the groups. Patients with T1D also had a significantly lower MV index in the CRA ($1.11 \pm 0.15$ vs. $1.24 \pm 0.23$; $P=0.010$). In the T1D group, a significant negative correlation was found between the level of glucose ($r=-0.58$; $P<0.001$), fructosamine ($r=-0.46$; $P=0.003$), 8-OHdG ($r=-0.48$; $P=0.002$) and the MV index in the CRA. At the same time, in this group fructosamine and 8-OHdG levels had a separate effect on the MV index (adjusted $R^2=0.38$, $P<0.001$).

Conclusion Higher glucose levels, the medium-term glucose level, and systemic oxidative stress could importantly reduce retinal vasodilatation during flickering light irritation in patients with T1D.

Vladimir Debelić1, Brigita Drnovšek Olup1, Bogomir Žižek2, Milan Skitek3, Aleš Jerin3
1University Eye Clinic, University Medical Center in Ljubljana, Ljubljana, Slovenia
2Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
3Institute for Clinical Chemistry and Biochemistry, University Medical Centre in Ljubljana, Ljubljana, Slovenia

Received: March 15, 2016
Accepted: September 15, 2016
Correspondence to:
Vladimir Debelić
University Eye Clinic, University Medical Center in Ljubljana
Grablovičeva 46
1000 Ljubljana, Slovenia
vladimir.debelic@masicom.net
Metabolic changes caused by hyperglycemia in type 1 diabetes (T1D) affect retinal cells’ function, resulting in functional disturbances in the vessels during the increased metabolic load of the retina (1). Before changes are detected in the function of ganglion cells, there are malfunctions in neurovascular coupling, with modified vascular autoregulation in the retina (2). There are various diagnostic methods available to measure the extent of vasodilatation disability (3-5). Retinal irritation with flickering light causes increased metabolic activity, particularly in the ganglion retinal cells, with subsequent vasodilation of the local vessels and an increased blood flow. In this regard, an important role is played by vasodilators such as nitric oxide, as well as derivatives of arachidonic acid. The impact of some metabolites, such as lactate and adenosine diphosphate, was also identified (6,7). The vasoactive molecules are released directly from the nerve cells and neuroglia as well as the endothelial cells in the vessel walls (6,7).

Studies so far have discovered negative correlations between the retinal arterial dilatation during flickering light stimulation and blood glucose level 2 hours after oral glucose ingestion in patients with T1D (8) and in a healthy group (5). Retinal venous dilation in similar conditions was negatively correlated with glycated hemoglobin in patients with diabetes in one study (9), but another study did not show the same findings (8). The correlations between retinal vessel dysfunction and other systemic biochemical factors have not been investigated so far. Therefore, the aim of our study was to determine whether higher glucose and medium-term (1-2 weeks) glucose plasma level indicated by fructosamine, higher systemic oxidative stress indicated by 8-hydroxy-2’-deoxyguanosine (8-OHdG), and higher levels of triglyceride, cholesterol, and lipoproteins decrease mean velocity (MV) index of central retinal artery (CRA) in patients with T1D.

PATIENTS AND METHODS

The study was carried out from July 2008 to January 2015 at the University Eye Hospital of the University Medical Centre in Ljubljana. All eligible patients with previously diagnosed T1D were participants in the diabetic retinal screening program at the outpatient department of the hospital. The patient group was randomly selected from a larger group of patients using random number generator. Healthy hospital employees were selected for the control group by the same technique from the list of employees taking into account approximately the same age and sex ratio compared to the patient group. The participants were invited to take part in the study and informed of the purpose and side effects of the research, and signed the informed consent form. Ethical approval was received from the Medical Ethics Committee of the Republic of Slovenia in the document number 38/02/07. To begin, a test sample size of 20 participants was assembled and the final size of both groups was determined by power and sample-size analysis for a two-sample means test. We needed a total number of 80 participants divided into two equal groups to detect the significant mean difference of the MV indices. The study involved 78 participants, who were divided into two approximately equal groups. Patient group comprised 41 patients with T1D and the control group comprised 37 participants without diabetes. By selecting patients with T1D, we avoided the effect of insulin resistance in type 2 diabetes (T2D), which could further affect the function of the vascular system. Also, patients with T2D more frequently suffer from obesity, arterial hypertension, hypertriglyceridemia, or lower high-density lipoprotein (HDL) levels (10), which might further affect the study results. In order to exclude the effect of age, the participants in both groups were of the same age (32.6±6.7 years in the T1D group and 30.3±5.1 years in the control group; P=0.102). All the participants with untreated hypertension and a blood pressure of 140/90 mm Hg or more were not included in the study. Blood pressure was measured on the upper arm using a pressure monitor while the participants were sitting in an upright position. Individuals with a body mass index of more than 30 were also not included.

All the participants underwent an ophthalmologic examination of the anterior and posterior segments of the eye using a slit lamp, and the clinical documentation of patients with T1D was reviewed. The visual acuity with optical correction of all the participants was measured using a Snellen chart, and individuals with a VA of less than 20/25 were not included. Patients with T1D and any sign of diabetic retinopathy were also not included, as well as individuals with opaque optical media in the cornea, anterior segment, intraocular lens, and the vitreous body, and other retinal diseases (hypertensive retinopathy, occlusion of retinal vessels, etc.). IOP was measured using Goldmann applanation tonometry. All patients with glaucoma and participants with an IOP of over 21 mm Hg were not included.

Measuring the MV in the CRA using a Doppler ultrasound device

The MV was measured using the ATL HDI 1000 Ultrasound System (ATL Ultrasound Inc., Bothell, WA,
USA), a Doppler ultrasound device, with a linear transducer 11.5 L. All the measurements were made from 09.00 am to 11:59 am by one person in a darkened room. Participants were allowed to have a five-minute rest period before the measurement and were lying in a horizontal position. The ultrasonic transducer was used to measure the MV in the CRA, just behind the eye in the optic nerve, through the upper eyelid with a fixed eye view at a 45-degree angle. In the first phase, three measurements were made in basal conditions, without light irritation, at five-minute intervals. In the second phase, the eyeball was exposed to 45 seconds of 8 Hz halogen lamp flickering light stimulation with a MV measurement made at the end of the irritation. Two similar measurements were repeated during five-minute intervals. The Pulsed-Wave Doppler Mode was used for a hemodynamic assessment of the MV in the CRA. The MV index is calculated from the ratio of two measurements:

\[
\text{MV index} = \frac{\text{MV during flickering light (cm/s)}}{\text{MV in basal conditions (cm/s)}}
\]

The measurements of the MV in the CRA in basal conditions were carried out by one person using a Doppler ultrasound device on 12 healthy participants in order to assess their repeatability. The measurements were carried out three times in three sessions, with one week between them.

**Biochemical analysis**

Venous blood was taken from the cubital vein of the fasted participants, without using any additives, between 08.00 AM and 09.00 AM. All the biochemical investigations were carried out at the Institute of Clinical Chemistry and Biochemistry of the University Medical Centre in Ljubljana. After blood centrifugation, the serum was stored at -20°C for further analyses. All the investigations were conducted simultaneously. Using enzymatic calorimetric methods, we determined the level of glucose, triglycerides, and cholesterol. Fructosamine was measured using the colorimetric method. HDL was measured using the direct method. The procedure was performed on an ADVIA automated analyzer (Siemens Diagnostics, Erlangen, Germany). Using the Friedewald formula, we determined the level of low-density lipoprotein (LDL) particles. The level of 8-OHdG in the serum was measured using the enzyme-linked immunosorbent assay method (JICA, Shizuoka, Japan).

**Statistical analysis**

Normally distributed variables are presented as means and standard deviations and not-normally distributed variables are presented as medians and ranges. To assess the normality of distribution, we used the Shapiro-Wilk test. In both groups of participants, levels of cholesterol, HDL, LDL, and the MV values during the basal conditions were normally distributed. In patients with T1D, unlike the control group, fructosamine level and the MV index were normally distributed. In both groups, the levels of glucose, 8-OHdG and triglycerides, and the MV value during flickering light, were not normally distributed. The parametric variables were analyzed using an independent two-sample t test and the Pearson product moment correlation coefficient. For the nonparametric variables, we used the Mann-Whitney U-Test and the Spearman rank correlation coefficient test. Multiple linear regression was used to determine the influence of independent prognostic variables. We estimated the reproducibility of the measurements using the coefficient of variation. P values <0.05 were considered statistically significant. All statistical calculations were performed using IBM SPSS Statistics v. 20 software (IBM, Armonk, NY, USA).

**RESULTS**

There were no differences in sex (18 men and 23 women in the T1D group vs 16 men and 21 women in the control group; \(P=0.963\)) and age between the groups (32.6±6.7 years and 30.3±5.1 years, respectively; \(P=0.102\)). The patients had T1D for 18.1±7.9 years. 15 patients had an insulin pump, while the rest were treated with insulin injections. 5 patients with T1D and only one control participant were treated for hypertension before the study, but the difference was not significant (\(P=0.124\)). Systolic (SBP)/diastolic blood pressure (DBP) was lower than 140/90 mm Hg in all participants. There were no significant differences between the groups in either SBP (T1D group 117.7±12.7 mm Hg and controls 119.7±12.4 mm Hg, \(P=0.480\)) or DBP (74.2±8.4 mm Hg and 72.2±8.9 mm Hg, respectively, \(P=0.308\)). 2 control participants and 8 patients with T1D were smokers, but the difference in smoking status between the groups was not significant (\(P=0.063\)).

The IOP was approximately the same in both groups (15.8 mm Hg ±3.4 in T1D group vs 15.0±5.4 mm Hg in controls; \(P=0.424\)). Patients with T1D had significantly higher average levels of glucose (\(P<0.001\)), fructosamine (\(P<0.001\)), and 8-OHdG (\(P<0.001\)). However, there were no significant differences in the levels of triglycerides, cholesterol, LDL, and HDL (Table 1). 58.5% of patients with T1D and 5.4% of controls had fasting glucose level higher than 6.1 mmol/L.
In patients with T1D, there were significant positive correlations between the level of glucose and fructosamine \((r = 0.80; P < 0.001)\) and the level of glucose and 8-OHdG \((r = 0.45; P = 0.003)\). Similarly, in the control group there was a positive correlation between the level of glucose and fructosamine \((r = 0.51; P = 0.001)\) but there was no correlation between the level of glucose and 8-OHdG \((r = 0.23; P = 0.143)\). Multiple linear regression showed that fructosamine and 8-OHdG levels had a separate effect on the MV index in patients with T1D. The regression model explained the greatest proportion of the variability of the MV index \((R^2 \text{ of the model} = 0.38; P < 0.001)\) (Table 2).

Patients with T1D had significantly lower average MV in the CRA in basal conditions \((P = 0.019)\) and during flickering light stimulation \((P < 0.001)\). The MV index was also significantly lower in that group \((P = 0.010)\) (Table 3).

The repeatability of the three measurements was tested on 12 participants. The coefficient of the variation, or repeatability, of measurements of the MV was 5.6%. The correlation coefficient between the measurements of this parameter by the same investigator was 0.89 \((P < 0.001)\).

### Table 1. Biochemical analyses in patients with type 1 diabetes and control group

| Variable                              | Type 1 diabetes \((n = 41)\)       | Control group \((n = 37)\)       | \(P\)         |
|---------------------------------------|-----------------------------------|---------------------------------|---------------|
| Glucose (mmol/L)                      | 7.3 (4.4-8.6)*                    | 4.0 (3.3-4.5)                   | <0.001*       |
| Fructosamine (mg/L)                   | 392 ± 103                        | 217 (189-252)                   | <0.001*       |
| 8-hydroxy-2'-deoxyguanosine (µg/L)    | 28.08 (22.13-35.82)              | 12.43 (6.35-22.25)             | <0.001*       |
| Cholesterol (mmol/L)                  | 4.7 ± 0.7                        | 4.8 ± 0.9                      | 0.531         |
| High density lipoproteins (mmol/L)    | 1.4 ± 0.3                        | 1.4 ± 0.3                      | 0.793         |
| Low density lipoproteins (mmol/L)     | 2.7 ± 0.7                        | 2.6 ± 0.7                      | 0.645         |
| Triglyceride (mmol/L)                 | 0.9 (0.7-1.1)                    | 1.0 (0.8-1.3)                  | 0.108*        |

*Mean ± standard deviation for normally distributed variables.
†Mann-Whitney U-test; unmarked independent two-sample \(t\) test.

### Table 2. Model of multiple linear regression for analyzing the influence of different independent variables on the mean velocity index in patients with type 1 diabetes

| Variable                              | \(b\) | \(P\)       | \(R^2\) of the sequence | \(R^2\) of the model |
|---------------------------------------|-------|-------------|--------------------------|-----------------------|
| 8-hydroxy-2'-deoxyguanosine           | −0.0047 | <0.001     | 0.28                     | 0.38                  |
| Fructosamine                          | −0.00048 | 0.013     | 0.38                     | \(P < 0.001\)         |

*b = regression coefficient; \(R^2\) = coefficient of determination.

### Table 3. The mean velocity (MV) in the central retinal artery and the MV index in patients with type 1 diabetes and the control group

| Variable                              | Type 1 diabetes \((n = 41)\) | Control group \((n = 37)\) | \(P\)         |
|---------------------------------------|-------------------------------|----------------------------|---------------|
| MV in basal conditions (cm/s)         | 6.44 ± 1.70                   | 7.44 ± 1.99                | 0.019         |
| MV during flickering light (cm/s)     | 6.8 (5.83-7.75)               | 9.10 (7.41-10.56)          | <0.001*       |
| MV index                              | 1.11 ± 0.15                   | 1.17 (1.08-1.36)           | 0.010*        |

*Mean ± standard deviation for normally distributed variables.
†Mann-Whitney U-Test; unmarked independent two-sample \(t\) test.

### Table 4. Correlation between mean velocity index and clinical or biochemical variables in patients with type 1 diabetes and the control group

| Variable                              | Type 1 diabetes \((n = 41)\) | Control group \((n = 37)\) | \(P\)       |
|---------------------------------------|-------------------------------|----------------------------|-------------|
| Glucose                               | −0.58*                        | 0.23†                      | 0.166       |
| Fructosamine                          | −0.46                         | 0.33†                      | 0.045       |
| 8-OHdG                                | −0.48†                        | 0.18†                      | 0.276       |
| Cholesterol                           | −0.12                         | 0.40†                      | 0.014       |
| HDL                                   | −0.10                         | 0.29†                      | 0.087       |
| LDL                                   | 0.00010                       | 0.14†                      | 0.403       |
| Triglyceride                          | −0.16†                        | −0.18†                     | 0.293       |

*SBP – systolic blood pressure; DBP – diastolic blood pressure; IOP – intraocular pressure; 8-OHdG – 8-hydroxy-2'-deoxyguanosine; HDL – high density lipoproteins; LDL – low density lipoproteins; \(r\) – coefficient of correlation.
†Spearman rank correlation coefficient; unmarked Pearson product moment correlation coefficient.
In patients with T1D, a significant negative correlation was found between the MV index and the level of glucose ($r = -0.58; P < 0.001$), fructosamine ($r = -0.46; P = 0.003$), and 8-OHdG ($r = -0.48; P = 0.002$). In the control group, there was a comparable significant positive correlation between the MV index and the fructosamine level. In patients with T1D, there was no significant correlation between participants' age, duration of diabetes, SBP, DBP, IOP, cholesterol levels, HDL, LDL, and triglycerides with the MV index (Table 4 and Figures 1 and 2).

**DISCUSSION**

Using a Doppler ultrasound examination on Pulsed-Wave Doppler Mode, we observed lower ability of retinal vasoregulation during increased retinal metabolic load in patients with T1D. Similar results using the same technique have not been published in diabetic patients recently but lower retinal vasodilation in similar conditions was found using another technique (Dynamic Vessel Analyzer) (11,12). Our results indicate that diabetes has a significant impact on the reduction of vasodilatation during increased retinal metabolism due to flickering light stimulation. Neurodegenerative changes in the retina occur early in the course of diabetes and affect neurovascular coupling. In particular, there are interferences in the release of the vasodilators when metabolic requirements are high (6,13,14). Direct vascular failure in diabetes takes place only afterwards (2).

An ultrasound examination using the Pulsed-Wave Doppler Mode provides a high degree of precision, with appropriate reproducibility, for measuring blood velocity in the orbital vessels and corresponds to the intra-subject reproducibility of our measurements of the MV in the CRA (15,16). Taking these results into account, we can conclude that the method is reliable for measuring the blood flow in the CRA and that it can be used for further investigations.

In appropriately controlled and treated patients with diabetes, the fasting glucose level in the morning should be in the normal range. In insulin-treated patients with T1D we found higher plasma glucose level than in controls, and in more than half of the patients it was above the upper limit of the normal range. The majority of our patients had
Higher glucose level and systemic oxidative stress decrease mean velocity index of retinal artery

Debelić et al: Higher glucose level and systemic oxidative stress decrease mean velocity index of retinal artery
before the beginning of the study. Antihypertensive drugs and treated arterial hypertension could affect the dysfunction of the retinal blood vessels during the flickering light irritation and the accuracy of measurements of MV in CRA.

The significance of the functional vascular disorder of the retina during flickering light stimulation in the formation and prognosis of diabetic retinal pathology is not yet known. Despite the observed connection between systemic oxidative stress and functional vascular disorders of the retina, measurement of the B-OHdG level during screening of the patients with T1D has no clinical significance. Further studies are required to identify possible connections between retinal functional vascular disorders and clinically undetectable morphological changes in the retina, the probability of occurrence and rate of progression of diabetic retinopathy, and the possibility of severe and proliferative diabetic retinopathy. If these hypotheses are accepted, the measurement of retinal functional vascular disorder, and even more systemic biochemical markers associated with it, will play an important role in long-term screening of the patients with T1D.

Acknowledgments The authors thank all participants involved in the study.

Funding The study was sponsored by the Fund for Research in the University Medical Centre in Ljubljana (70096).

Ethical approval received from the Medical Ethics Committee of the Republic of Slovenia in document No. 38/02/07.

Authorship declaration DV performed the clinical investigation, data acquisition, statistical analysis, and wrote the manuscript. DOB and ŽB conceived and performed biochemical investigations, and reviewed the manuscript.

Competing interests All authors completed the Unified Competing Interest form at www.cmj.org/ccd_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Lasta M, Pemp B, Schmidl D, Boltz A, Kaya S, Palkovits S, et al. Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes. Invest Ophthalmo Vis Sci. 2013;54:842-7. Medline:23307962 doi:10.1167/iovs.12-10873
2. Simo R, Hernandez C. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25:23-33. Medline:24183659 doi:10.1016/j.tem.2013.09.005
3. Baydar S, Adapinar B, Kebapci N, Bal C, Topbas S. Colour Doppler ultrasound evaluation of orbital vessels in diabetic retinopathy. Australas Radiol. 2007;51:230-5. Medline:17504313 doi:10.1111/j.1440-1673.2007.01717.x
4. Ludovico J, Bernardes R, Pires I, Figueira J, Lobo C, Cunha-Vaz J, et al. Alterations of retinal capillary blood flow in preclinical retinopathy in subjects with type 2 diabetes. Graefes Arch Clin Exp Ophthalmol. 2003;241:181-6. Medline:12644940 doi:10.1007/s00417-002-0520-9
5. Dorner GT, Garhofer G, Huemer KH, Riva CE, Wolz M, Schmetterer L, et al. Hyperglycemia affects flicker-induced vasodilation in the retina of healthy subjects. Vision Res. 2003;43:1495-500. Medline:12767316 doi:10.1016/S0042-6989(03)00170-6
6. Pournaras CJ, Rungger-Brandle E, Riva CE, Hardarson SH, Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res. 2008;27:284-330. Medline:18448380 doi:10.1016/j.preteyeres.2008.02.002
7. Noonan JE, Lamoureux EL, Sarosy M. Neuronal activity-dependent regulation of retinal blood flow. Clin Experiment Ophthalmol. 2015;43:629-34. Medline:25824961 doi:10.1111/cio.12530
8. Schiel R, Vilser W, Kovar F, Kramer G, Braun A, Stein G, et al. Retinal vessel response to flicker light in children and adolescents with type 1 diabetes mellitus and overweight or obesity. Diabetes Res Clin Pract. 2009;83:335-40. Medline:19100645 doi:10.1016/j.diabres.2008.11.001
9. Heitmar R, Varma C, De P, Lau YC, Blann AD. The relationship of systemic markers of renal function and vascular function with retinal blood vessel responses. Graefes Arch Clin Exp Ophthalmol. 2016;254:2257-65 Medline:27436082 doi:10.1007/s00417-016-3432-9
10. Song SH. Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. BMJ Open Diabetes Res Care. 2015;5:e000044. Medline:25713725 doi:10.1136/bmjdr-2014-00004
11. Pemp B, Garhofer G, Weigert G, Schmetterer L. Reduced retinal vessel response to flicker stimulation but not to exogenous nitric oxide in type 1 diabetes. Invest Ophthalmo Vis Sci. 2009;50:4029-32. Medline:19366238 doi:10.1167/iovs.08-3260
12. Leclaire-Collet A, Audou I, Aout M, Girmens JF, Sofroni R, Erginay A, et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmo Vis Sci. 2011;52:2861-7. Medline:21282578 doi:10.1167/iovs.10-5960
13. Cuypers MH, Kasanardjo JS, Polak BC. Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. Graefes Arch Clin Exp Ophthalmol. 2000;238:935-41. Medline:11196354 doi:10.1007/s004170000207
14. Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res. 2012;31:377-406. Medline:22580107 doi:10.1016/j.preteyeres.2012.04.004
15. Dellaire C, Lava M, Verticchio Vercellin AC, Cutolo CA, Tinelli C, De Silvestri A, et al. Reproducibility of retinal blood flow velocity measurements in normal subjects using two different CDI devices. Radiol Med (Torino). 2015;120:737-44. Medline:25690710
Debelić et al. 441

Higher glucose level and systemic oxidative stress decrease mean velocity index of retinal artery.

www.cmj.hr

doi:10.1007/s11547-015-0522-4

16 Luksch A, Lasta M, Polak K, Fuchs-Jager-Mayrl G, Polska E, Garhofer G, et al. Twelve-hour reproducibility of retinal and optic nerve blood flow parameters in healthy individuals. Acta Ophthalmol. 2009;87:875-80. Medline:18976308 doi:10.1111/j.1755-3768.2008.01388.x

17 Shin ES, Sorenson CM, Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res. 2014;9:362-73. Medline:25667739

18 Malmstrom H, Walldius G, Grill V, Jungner I, Gudbjornsdottr S, Hammar N. Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies–cross-sectional and longitudinal experience from the AMORIS cohort. PLoS One. 2014;9:e111463. Medline:25353659 doi:10.1371/journal.pone.0111463

19 Pemp B, Garhofer G, Lasta M, Schmidl D, Schmetterer L. The association between high-sensitive C-reactive protein and retinal hemodynamics in type 1 diabetes patients with non-proliferative diabetic retinopathy. Acta Ophthalmologica. 2010;88. doi:10.1111/j.1755-3768.2010.4116.x

20 Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92:548-51. Medline:18369071 doi:10.1136/bjo.2007.130542

21 Wakabayashi Y, Usui Y, Shibautchi Y, Uchino H, Goto H. Increased levels of 8-hydroxydeoxyguanosine in the vitreous of patients with diabetic retinopathy. Diabetes Res Clin Pract. 2010;89:e59-61. Medline:20591522 doi:10.1016/j.diabres.2010.05.032

22 Wu LL, Chioo CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetes. Clin Chim Acta. 2004;339:1-9. Medline:14687888 doi:10.1016/j.cccn.2003.09.010

23 Maahs DM, Kinney GL, Wadwa P, Ell-Bergeon JK, Dabelea D, Hokanson J, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28:301-6. Medline:15677783 doi:10.2337/diacare.28.2.301

24 Verges B. Lipid disorders in type 1 diabetes. Diabetes Metab. 2009;35:353-60. Medline:19733492 doi:10.1016/j.diabet.2009.04.004